New Risk • Jul 02
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$5.5m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$5.5m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Revenue is less than US$1m (CA$155k revenue, or US$109k). Minor Risk Market cap is less than US$100m (CA$47.1m market cap, or US$33.2m). Announcement • Jun 24
Onco-Innovations Engages Nanosoft Polymers to Advance Polymer and Drug Delivery Development for Onc010 Onco-Innovations entered into a services agreement with Nanosoft Polymers, a specialized polymer engineering and drug delivery company, to support the continued development of ONC010, the Company's lead nanoparticle-formulated Polynucleotide Kinase Phosphatase inhibitor. Under the agreement, Nanosoft will provide polymer process development, analytical characterization, scale-up support, formulation optimization, and technology transfer services for Onco's proprietary PEO-PBCL polymer platform. The work is intended to strengthen the manufacturing and formulation foundation of ONC010 as research and development efforts advance through IND-enabling development and preparation for future clinical studies. Nanosoft brings extensive experience in polymer synthesis, nanoparticle drug delivery systems, process optimization, analytical characterization, and scalable manufacturing approaches for therapeutic applications. The program will focus on establishing a robust, reproducible, and scalable polymer manufacturing process while enhancing analytical methods and quality controls necessary to support future manufacturing, regulatory, and clinical development activities. Nanosoft will also support process scale-up and technology transfer initiatives designed to facilitate future GMP manufacturing and commercial development opportunities. Nanosoft's work will complement ongoing chemistry, manufacturing and controls activities being conducted by Dalton Pharma Services and preclinical development activities being conducted by Nucro-Technics. Together, these organizations form a growing development ecosystem supporting the advancement of ONC010 toward First-in-Human clinical evaluation. Announcement • Jun 21
Onco-Innovations Limited Announces Chief Financial Officer Changes Onco-Innovations Limited announced the appointment of Mr. Dave Antony as Chief Financial Officer, effective June 19, 2026. Mr. Antony replaces Mr. Nico Mah. 
